Drugs.com - New Drug Approvals

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral...

Jun 12, 2025 - 01:40
 0
U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral...
Read More

Tags:

Previous Article

New report on Samui hotels and tourism

Next Article

Almost One-Quarter of U.S. Firearm Suicides May Occur Outside the Home

Related Posts

FDA Approves HemiClor (chlorthalidone) for the Treatment of Hypertension

FDA Approves HemiClor (chlorthalidone) for the Treatmen...

May 18, 2025  0

FDA Approves Imfinzi (durvalumab) for Muscle Invasive ...

May 12, 2025  0

FDA Approves mNEXSPIKE (COVID-19 Vaccine, mRNA) to Prevent COVID-19

FDA Approves mNEXSPIKE (COVID-19 Vaccine, mRNA) to Prev...

Jun 3, 2025  0